Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tacrolimus filed in Japan for wider myasthenia gravis use

This article was originally published in Scrip

Executive Summary

Astellashas made a Japanese submission to extend the use of its immunosuppressant Prograf (tacrolimus) in myasthenia gravis (MG) patients. The product was approved in 2000 for post-thymectomy MG patients in whom steroids are ineffective or inappropriate, and the new filing seeks clearance for all types of MG. The autoimmune disorder is characterised by muscle weakness from the disruption of neuromuscular transmission, and tacrolimus acts to suppress the production of lymphocyte-mediated cytokines and anti-acetylcholine receptor antibodies.

You may also be interested in...



Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro

Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.

ASCO 2020: Pevonedistat Shows Promise In Higher-Risk MDS

Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.

ASCO 2020: Can Xtandi PROSPER In Prostate OS Data Battle?

While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.

Topics

UsernamePublicRestriction

Register

AP000837

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel